Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY19 results · Apr–Jun 2018
Sun Pharma Advanced Research Company reported revenue from operations of ₹16.81 crore and net loss of ₹64.48 crore for Q1 FY19 (Apr–Jun 2018), on a standalone basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 16.81 | — | — | — | — |
| Other income | 1.23 | — | — | — | — |
| Total income | 18.04 | — | — | — | — |
| Profit before tax | (64.48) | — | — | — | — |
| Net profit for the period | (64.48) | — | — | — | — |
| EPS, basic (₹) | (2.57) | — | — | — | — |
| Net margin (%) | -383.6 | — | — |
Standalone
- Filed with BSE
- 31 Jul 2018, 12:59 IST
- Board meeting
- 30 Jul 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE